Home » Genzyme Rare-Disease Drug Denied Accelerated Decision by FDA
Genzyme Rare-Disease Drug Denied Accelerated Decision by FDA
Genzyme and its partner Isis Pharmaceuticals said the U.S. Food and Drug Administration accepted their potential treatment for a rare, genetic form of extremely high cholesterol for review, after it was initially sent to the agency in March.
Boston Business Journals
Boston Business Journals
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May